ImExHS Limited operates as an imaging software as a service and ancillary service provider in Australia and internationally.
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$1.33|
|52 Week High||AU$1.32|
|52 Week Low||AU$2.54|
|1 Month Change||-8.28%|
|3 Month Change||-21.77%|
|1 Year Change||-24.00%|
|3 Year Change||-14.19%|
|5 Year Change||n/a|
|Change since IPO||-1.48%|
Recent News & Updates
Market Sentiment Around Loss-Making ImExHS Limited (ASX:IME)
ImExHS Limited ( ASX:IME ) is possibly approaching a major achievement in its business, so we would like to shine some...
|IME||AU Healthcare Services||AU Market|
Return vs Industry: IME underperformed the Australian Healthcare Services industry which returned 46.7% over the past year.
Return vs Market: IME underperformed the Australian Market which returned 20.2% over the past year.
Stable Share Price: IME is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: IME's weekly volatility (8%) has been stable over the past year.
About the Company
ImExHS Limited operates as an imaging software as a service and ancillary service provider in Australia and internationally. It is involved in developing and selling Hiruko software platform that comprises radiology information system, which manages the workflow management system with a patient data and image distribution system, as well as picture archiving and communication system that allows healthcare organization to capture, store, view, and share radiology images. The company was founded in 2012 and is headquartered in Mascot, Australia.
ImExHS Fundamentals Summary
|IME fundamental statistics|
Is IME overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|IME income statement (TTM)|
|Cost of Revenue||AU$6.97m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.12|
|Net Profit Margin||-34.58%|
How did IME perform over the long term?See historical performance and comparison
Is ImExHS undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate IME's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate IME's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: IME is unprofitable, so we can't compare its PE Ratio to the Global Healthcare Services industry average.
PE vs Market: IME is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate IME's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: IME is good value based on its PB Ratio (3.2x) compared to the AU Healthcare Services industry average (3.8x).
How is ImExHS forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: IME is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.9%).
Earnings vs Market: IME is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: IME's is expected to become profitable in the next 3 years.
Revenue vs Market: IME's revenue (34.2% per year) is forecast to grow faster than the Australian market (5.5% per year).
High Growth Revenue: IME's revenue (34.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: IME's Return on Equity is forecast to be high in 3 years time (23.7%)
How has ImExHS performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: IME is currently unprofitable.
Growing Profit Margin: IME is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: IME is unprofitable, and losses have increased over the past 5 years at a rate of 27.3% per year.
Accelerating Growth: Unable to compare IME's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IME is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (39.5%).
Return on Equity
High ROE: IME has a negative Return on Equity (-29.51%), as it is currently unprofitable.
How is ImExHS's financial position?
Financial Position Analysis
Short Term Liabilities: IME's short term assets (A$13.1M) exceed its short term liabilities (A$3.9M).
Long Term Liabilities: IME's short term assets (A$13.1M) exceed its long term liabilities (A$1.4M).
Debt to Equity History and Analysis
Debt Level: IME's debt to equity ratio (7.5%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if IME's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: IME has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: IME has sufficient cash runway for 1.6 years if free cash flow continues to reduce at historical rates of 31.7% each year.
What is ImExHS current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate IME's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate IME's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if IME's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if IME's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of IME's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Dr. German Arango is Chief Executive Officer and Managing Director at ImExHS Limited since August 28, 2018. Dr. Arango has been a Director of ImExHS Limited (formerly known as Omni Market Tide Ltd.) since...
CEO Compensation Analysis
Compensation vs Market: German's total compensation ($USD273.12K) is about average for companies of similar size in the Australian market ($USD302.72K).
Compensation vs Earnings: German's compensation has been consistent with company performance over the past year.
Experienced Management: IME's management team is not considered experienced ( 1 years average tenure), which suggests a new team.
Experienced Board: IME's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: IME insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 37.8%.
ImExHS Limited's employee growth, exchange listings and data sources
- Name: ImExHS Limited
- Ticker: IME
- Exchange: ASX
- Founded: 2012
- Industry: Health Care Technology
- Sector: Healthcare
- Market Cap: AU$43.705m
- Shares outstanding: 32.86m
- Website: https://www.imexhs.com
Number of Employees
- ImExHS Limited
- 122 O’Riordan Street
- New South Wales
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/17 07:04|
|End of Day Share Price||2021/10/15 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.